A staple cartridge assembly comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises a first fibrous, woven material and a second fibrous, woven material. The first fibrous, woven material comprises a density which is different than the density of the second fibrous, woven material. The tissue thickness compensator is configured to expand upon contact with a fluid in order to apply a compressive force to tissue captured within staples.

A staple cartridge assembly comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises a first fibrous, woven material and a second fibrous, woven material. The first fibrous, woven material comprises a density which is different than the density of the second fibrous, woven material. The tissue thickness compensator is configured to expand upon contact with a fluid in order to apply a compressive force to tissue captured within staples.

A staple cartridge assembly comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises a first fibrous, woven material and a second fibrous, woven material. The first fibrous, woven material comprises a density which is different than the density of the second fibrous, woven material. The tissue thickness compensator is configured to expand upon contact with a fluid in order to apply a compressive force to tissue captured within staples.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

A medical polymer device comprising a biodegradable polymer is provided, wherein the biodegradable polymer has a crystallinity of about 10% to about 80%, and preferably from about 20% to about 60%, wherein the medical polymer device comprises a small molecule organic compound which diffuses into the biodegradable polymer, the small molecule organic compound has a molecular weight of from about 100 to about 1000 Daltons, preferably from about 150 to about 500 Daltons, and more preferably from about 150 to about 250 Daltons, and the small molecule organic compound is non-evaporating or low-evaporating. The present invention also provides a method for preparing a medical polymer device according to the present invention as well as a method for modifying a medical polymer device made from a biodegradable polymer.

The technology concerns a construct comprising at least one tissular region and at least one polymeric region for use as an implant.

The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Compositions and methods for providing one or more platelet-derived hemostatic agents to a treatment site are provided. Compositions and methods may be directed to bandages, carrier materials, and closure devices. Compositions and methods may be directed to treatment of neoplasias, including cancers. The platelet-derived hemostatic agents may include chemotherapeutic agents.

The subject invention provides materials and methods for preventing, inhibiting or reducing biofilm formation and biofilm infections in subjects. The materials and methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases/disorders and rheumatic diseases/disorders.